How is Osteoarthritis Diagnosed?

Do not wait. It is very important that once you begin to experience osteoarthritis symptoms, you see a doctor, get a proper diagnosis, and start treatment right away. Many factors influence which therapies are right for you, including the status of your health, other medications you take, and if your osteoarthritis case is mild, moderate, or severe. The earlier you and your doctor work together, the sooner you can begin a treatment plan that’s right for you.

There are usually four steps to making a diagnosis of osteoarthritis:

Medical This is your doctor’s best tool to diagnosing osteoarthritis. Talk to your doctor about your symptoms, family history, and past medical conditions.
Physical Your doctor will look for typical signs of osteoarthritis, such as joint swelling or tenderness, and a loss in the range of joint motion.
Joint fluid After applying a local anesthetic, your doctor may take a small amount of fluid from your joint, called synovial fluid. A lab test of this fluid can help confirm osteoarthritis and rule out other conditions.
X-rays or MRI’s These images can show damage inside the joint. Your doctor will be looking for the deterioration of cartilage tissue that is typical of osteoarthritis.

Summary of Indications for Use

DUROLANE (3 mL): Symptomatic treatment of mild to moderate knee or hip osteoarthritis. In addition, DUROLANE has been approved for the symptomatic treatment associated with mild to moderate osteoarthritis pain in the ankle, shoulder, elbow, wrist, fingers, and toes.

DUROLANE (1 mL): Symptomatic treatment associated with mild to moderate osteoarthritis pain in the ankle, elbow, wrist, fingers, and toes.

Both DUROLANE and DUROLANE SJ are also indicated for pain following joint arthroscopy in the presence of osteoarthritis within three months of the procedure.

You should not use DUROLANE if you have infections or skin disease at the injection site. DUROLANE has not been tested in pregnant or lactating women, or children.

Risks can include transient pain, swelling and/or stiffness at the injection site. Full prescribing information can be found in product labeling.

DUROLANE, Bioventus and the Bioventus logo are registered trademarks of Bioventus LLC. NASHA is a registered trademark of Nestlé Skin Health S.A.

Patient information leaflet available here.

© 2019 Bioventus LLC.

^{*First introduced in the European Union in 2001.}

To learn more about DUROLANE or for contact information, please select your location to continue.

Cookie Law

Our website uses cookies, some of which are essential for this site to operate correctly and have already been set. For more information on managing, blocking or deleting cookies within your browser please refer to the references within our Privacy Policy. By using our site you accept the terms of our Privacy policy.

Settings